



PlantForm Corporation

Making life-saving
medicine
more **affordable**



AGM September 2014



PlantForm Opportunity

Game-changing technology platform

- Disrupts current cell-based drug manufacturing methods
- Tobacco-plant system cuts biologic drug manufacturing cost by 90%
- Significantly reduced facility costs

Virtually untapped market for biosimilar drugs

- \$80B of biologic drugs go off-patent through 2015

Validated production platform also has innovator drug potential

- HIV/AIDS and countermeasures to bioterrorism projects





Strong, diverse pipeline

Pipeline Drugs

Biosimilar
Herceptin®

Biosimilar
Avastin®

Niche biosimilar
drugs

HIV antibodies

Anti-bioterrorism
products

Potential Market Size

\$ 7bn

\$ 6bn

~\$ 1bn each

BILL & MELINDA
GATES foundation



Market Entry

2017

2018-2022

Ongoing
revenue
stream



Achievements in last 12 months

- Established Joint Venture in Brazil with PharmaPraxis



“Partners to Market” Strategy

Global Pharma



Category leaders in biologics or small molecules

Global sales and marketing reach

Regional Pharma



Regional strength in key area(s)

Strategic intent to enter biosimilar market

Generic



Financial resources and presence in biosimilar market (or intent to enter)

Ability to build sales force



'PlantPraxis' Joint Venture



PharmaPraxis, Brazil and PlantForm, Canada collaboration and license agreement (2014)

- To develop, manufacture and commercialize drugs using PlantForm's plant expression system
- Targets are biosimilar and/or biobetter monoclonal antibody products
- Markets are Brazil and South America





'PlantPraxis' Joint Venture

Meetings in Brazil in September regarding the JV with

- Bio-Manguinhos
- Financiadora de Estudos e Projetos (FINEP, the Funding Authority for Studies and Projects)
- Brazilian Development Bank (BNDES)

The JV's first drug target will be a biosimilar/biobetter version of the oncology drug Avastin[®] (bevacizumab), in collaboration with the Fraunhofer Center for Molecular Biology.



Achievements in Last 12 Months

- Established Joint Venture in Brazil with PharmaPraxis
- \$2 million investment from Atlantic Assets Trust in the UK



Biosimilar Herceptin[®] Program

To date

Laboratory process



Technology transfer to
CMO



Animal efficacy study



Scale-up to 150 kg process



GLP/GMP manufacturing

Going forward

Safety and toxicology study



Characterization



Stability study



IND application



Phase I Clinical trial



Biosimilar Herceptin[®] Project Financing

- Legacy Partners Wealth Strategies Inc.: mandate to raise up to \$20 million through private share placement in central and western Canada
- Hallmark Capital Partners: to focus on raising funds from family offices in the United States
- Bloom Burton & Co.: engaged for strategic advisory services to support the company's growth and development



Achievements in last 12 months

- Established Joint Venture in Brazil with PharmaPraxis
- \$2 million investment from Atlantic Assets Trust in the UK
- Contract to use our platform technology to produce a drug for Prairie Plant Systems, Saskatoon



Prairie Plant Systems

- PlantForm has successfully completed a contract with Prairie Plant Systems Inc.
- Involved Prairie Plant Systems expressing an innovative biologic drug product using our plant-based system.
- Prairie Plant Systems is a privately held plant biotech company based in Saskatoon, Canada.



Prairie Plant
Systems Inc.



Other Potential Contracts and Grants

- Ongoing discussions with a major U.S. biotechnology company for a research contract to evaluate production of up to 5 of their drugs in our system.
- Ongoing discussions with Canada and the U.S. governments on Ebola.
- Ongoing discussions with Defense Canada on a multiproduct drug development project in countermeasures to bioterrorism, moving from the University to the Company.
- Project extension application for HIV/AIDS project submitted to IRAP-CHTD (Gates Foundation).



Achievements in last 12 months

- Established Joint Venture in Brazil with PharmaPraxis
- \$2 million investment from Atlantic Assets Trust in the UK.
- Contract to use our platform technology to produce a drug for Prairie Plant Systems, Saskatoon
- **MaRS HealthKick 2014 competition winner (biotechnology and pharmaceuticals track)**





In The News

Al Jazeera America (Aug. 22)

Reuters (Aug. 17)

GaBI online (Aug. 22)

BioPharma-Reporter.com (July 23)




*The Exchange with
Amanda Lang*

CBC TV (Aug. 13)



New Member of Management Team



Don Stewart PhD
*President & CEO,
Founder*

Experience in drug development and management in the biotechnology industry

Craig Binnie PhD
*VP Drug
Development*

Experience in biologics drug development for pharma and biotech

David Cayea, BA
Chief Operating Officer

Experience in international business development in Europe, Middle East and North America

Chris Hall, PhD
*Chief Scientific
Officer, Founder*

Leading authority in plant biologics research

Ron Hosking, CA
Chief Financial Officer

CFO experience in both multinational and startup biotech companies and large pharmaceutical licensing deals





PlantForm Intellectual Property

Four families of patents

**Core platform
technology**

to 2028

**Very high yield
production system**

to 2031

**Biosimilar
trastuzumab
manufacturing
process**

to 2031

**Innovative drug
candidate**

to 2029

Notice of Allowance
from the U.S. Patent and
Trademark Office
(August 2014) that a
second patent will be
granted.



Expression System Name

Staff competition to name expression system:

***vivo*XPRESS™**



Corporate Objectives 2014: Status (1)

Technical Objectives		Status	
1	Manufacture biosimilar trastuzumab (biosimilar Herceptin®) for animal studies and Phase I clinicals:	<ul style="list-style-type: none">• Ongoing at Fraunhofer CMB, USA	✓
2	Advance regulatory submission strategy for biosimilar trastuzumab	<ul style="list-style-type: none">• Ongoing: manufacturing in progress• Characterization, animal & clinical studies designed	✓
3	Complete DARPA contract including delivery of product to U.S. government:	<ul style="list-style-type: none">• Completed contract• Delivered product	✓
4	Advance HIV/AIDS project to express further candidates and conduct animal efficacy study:	<ul style="list-style-type: none">• Advanced expression• Awaiting NRC IRAP-CHTD funding decision for animal study	✓



Corporate Objectives 2014: Status (2)

Financing Objectives		Status	
1	Secure matching funds for Atlantic Assets Trust investment	<ul style="list-style-type: none">• Atlantic Assets second round investment secured	✓
2	Advance Mandate with Emirates NBD bank	<ul style="list-style-type: none">• Mandate moved from ENBD to a Dubai-based consultant	✓
3	Advance financing of agreement with PharmaPraxis	<ul style="list-style-type: none">• Financing secured from Brazil	✓



Corporate Objectives 2015: Planned

Technical Objectives

- 1 Conduct animal toxicity studies with biosimilar Herceptin[®]
- 2 Initiate technology transfer to PharmaPraxis in Brazil
- 3 Advance sialation pathway research program with Ryerson University

Financing Objectives

- 1 Secure biosimilar Herceptin[®] project funding
- 2 Secure funds from Brazil for PlantPraxis Joint Venture
- 3 Secure contract research agreement(s)



PlantForm Corporation



Making life-saving
medicine
more **affordable**

plantformcorp.com